TY - JOUR
T1 - Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation
AU - Han, Kelong
AU - Peyret, Thomas
AU - Quartino, Angelica
AU - Gosselin, Nathalie H.
AU - Gururangan, Sridharan
AU - Casanova, Michela
AU - Merks, Johannes H.M.
AU - Massimino, Maura
AU - Grill, Jacques
AU - Daw, Najat C.
AU - Navid, Fariba
AU - Jin, Jin
AU - Allison, David E.
N1 - Publisher Copyright:
© 2015 Genentech Inc.
PY - 2016/1/1
Y1 - 2016/1/1
N2 - Aim: The aim of the present study was to evaluate the pharmacokinetics of bevacizumab and various dosing strategies for this agent in paediatric patients. Methods: Data were collected from 232 paediatric patients (1971 concentrations) in five studies, with a wide range of age (0.5 - 21 years), body weight (BWT; 5.9 - 125 kg), and regimens (5 - 15 mg kg-1 biweekly or triweekly). Data from 152 patients (1427 concentrations) and 80 patients (544 concentrations) were used for model building and external validation, respectively. Steady-state exposure was simulated under BWT-based, body surface area (BSA)-based, ideal body weight (IBW)-based, and tier-based doses. NONMEM and R were used for analyses. Results: Typical estimates of clearance, central volume of distribution (V1), and median half-life were 9.04 ml h-1, 2851 ml, and 19.6 days, respectively. Clearance decreased with increasing albumin. Clearance and V1 increased with BWT and were higher in male patients. Clearance and V1 were lower in children with primary central nervous system (CNS) tumours than in children with sarcomas, resulting in 49% higher trough (Cmin) and 29% higher peak (Cmax) concentrations. BWT-adjusted clearance and V1 remained unchanged across ages. Paediatric Cmin was similar to adult Cmin under all dosing strategies. Paediatric Cmax exceeded adult Cmax under tier-based doses. Conclusions: BWT-adjusted pharmacokinetic parameter estimates in paediatric patients were similar to those in adults, and similar across ages. Bevacizumab exposure was higher in children with primary CNS tumours than in children with sarcomas. BSA-based, IBW-based, and tier-based doses offered no substantial advantage over the BWT-based dose currently used in adults for bevacizumab. Given the similarity in pharmacokinetics among many monoclonal antibodies, this may help to develop practical paediatric dosing guidelines for other therapeutic antibodies.
AB - Aim: The aim of the present study was to evaluate the pharmacokinetics of bevacizumab and various dosing strategies for this agent in paediatric patients. Methods: Data were collected from 232 paediatric patients (1971 concentrations) in five studies, with a wide range of age (0.5 - 21 years), body weight (BWT; 5.9 - 125 kg), and regimens (5 - 15 mg kg-1 biweekly or triweekly). Data from 152 patients (1427 concentrations) and 80 patients (544 concentrations) were used for model building and external validation, respectively. Steady-state exposure was simulated under BWT-based, body surface area (BSA)-based, ideal body weight (IBW)-based, and tier-based doses. NONMEM and R were used for analyses. Results: Typical estimates of clearance, central volume of distribution (V1), and median half-life were 9.04 ml h-1, 2851 ml, and 19.6 days, respectively. Clearance decreased with increasing albumin. Clearance and V1 increased with BWT and were higher in male patients. Clearance and V1 were lower in children with primary central nervous system (CNS) tumours than in children with sarcomas, resulting in 49% higher trough (Cmin) and 29% higher peak (Cmax) concentrations. BWT-adjusted clearance and V1 remained unchanged across ages. Paediatric Cmin was similar to adult Cmin under all dosing strategies. Paediatric Cmax exceeded adult Cmax under tier-based doses. Conclusions: BWT-adjusted pharmacokinetic parameter estimates in paediatric patients were similar to those in adults, and similar across ages. Bevacizumab exposure was higher in children with primary CNS tumours than in children with sarcomas. BSA-based, IBW-based, and tier-based doses offered no substantial advantage over the BWT-based dose currently used in adults for bevacizumab. Given the similarity in pharmacokinetics among many monoclonal antibodies, this may help to develop practical paediatric dosing guidelines for other therapeutic antibodies.
KW - Bevacizumab
KW - Body surface area
KW - Central nervous system tumour
KW - Dosing strategy
KW - External validation
KW - Paediatric
UR - http://www.scopus.com/inward/record.url?scp=84953351685&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84953351685&partnerID=8YFLogxK
U2 - 10.1111/bcp.12778
DO - 10.1111/bcp.12778
M3 - Article
C2 - 26345283
AN - SCOPUS:84953351685
SN - 0306-5251
VL - 81
SP - 148
EP - 160
JO - British journal of clinical pharmacology
JF - British journal of clinical pharmacology
IS - 1
ER -